The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.y

Pleuroparenchymal fibroelastosis (PPFE)

Publications

Camus P, von der Thüsen J, Hansell DM, Colby TV

Pleuroparenchymal fibroelastosis: one more walk on the wild side of drugs?

The European respiratory journal 2014 Aug;44;289-96 — 2014 Aug — 289-96

Beynat-Mouterde C, Beltramo G, Lezmi G, Pernet D, Camus C, Fanton A, Foucher P, Cottin V, Bonniaud P

Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents.

The European respiratory journal 2014 Aug;44;523-7 — 2014 Aug — 523-7

Myers JL, Limper AH, Swensen SJ

Drug-induced lung disease: a pragmatic classification incorporating HRCT appearances.

Seminars in respiratory and critical care medicine 2003 Aug;24;445-54 — 2003 Aug — 445-54

Parish JM, Muhm JR, Leslie KO

Upper lobe pulmonary fibrosis associated with high-dose chemotherapy containing BCNU for bone marrow transplantation.

Mayo Clinic proceedings 2003 May;78;630-4 — 2003 May — 630-4

Taylor PM, O'Driscoll BR, Gattamaneni HR, Woodcock AA

Chronic lung fibrosis following carmustine (BCNU) chemotherapy: radiological features.

Clinical radiology 1991 Nov;44;299-301 — 1991 Nov — 299-301

Crittenden D, Tranum BL, Haut A

Pulmonary fibrosis after prolonged therapy with 1,3-bis (2-chloroethyl)-1-nitrosourea.

Chest 1977 Sep;72;372-3 — 1977 Sep — 372-3